A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

CARACTERÍSTICAS DE LOS PACIENTES, PATRONES DE TRATAMIENTO Y RESULTADOS DE LOS PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO AVANZADO CON MUTACIONES DE INSERCIÓN EN EL EXÓN 20 DEL EGFR: REVISIÓN ETROSPECTIVA OBSERVACIONAL NO INTERVENCIONISTA DE HISTORIAS CLÍNICAS EN ESPAÑA. ESTUDIO ERMEX-20.

ENHANCE: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING MAGROLIMAB IN COMBINATION WITH AZACITIDINE VERSUS AZACITIDINE PLUS PLACEBO IN TREATMENT-NAÏVE PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME.

ESTUDIO FASE II, ALEATORIZADO, PARA EVALUAR LA INCIDENCIA DE DISCONTINUACIÓN DEBIDA A DIARREA EN LOS 3 PRIMEROS CICLOS DE TRATAMIENTO EN PACIENTES CON CÁNCER DE MAMA PRECOZ HER2 POSITIVO (HER2+), RECEPTOR HORMONAL POSITIVO (RH+), TRATADOS CON NERATINIB MÁS LOPERAMIDA VERSUS NERATINIB CON ESCALADA INICIAL DE DOSIS MÁS LOPERAMIDA (SEGÚN NECESIDAD) VERSUS NERATINIB MÁS LOPERAMIDA MÁS COLESEVELAM

ESTUDIO OBSERVACIONAL AMBISPECTIVO DEL TRATAMIENTO DE LEUCEMIA LINFOCÍTICA nCRÓNICA/LINFOMA LINFOCÍTICO DE CÉLULAS PEQUEÑAS EN PRIMERA LÍNEA CON IBRUTINIB + VENETOCLAX EN PRÁCTICA CLÍNICA HABITUAL EN ESPAÑA. ESTUDIO LIVE

A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis IPF

A double-blind randomized placebo-controlled dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppression versus stopping immunosuppression at 6 months to safely prevent human leukocyte antigen (HLA) sensitization in patients with late renal graft failure

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MOS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)

A multicenter, open label, randomized, Phase II trial to investigate soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pembrolizumab (PD-1 antagonist) for first line treatment of subjects with unresectable recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

A multicenter, single-arm, open-label, extension, rollover study to evaluate. The long-term safety and efficacy of Ocrelizumab in patients with multiple Sclerosis

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

A Phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors, followed by an expansion part to assess safety and preliminary anti-tumor activity

A PHASE 1/2 STUDY OF CPI­0209 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer

A PHASE 1/3 STUDY TO EVALUATE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS